



February 24, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation of reaffirmation of Credit Ratings

Ref.: Regulation 30 & 51 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulations 30 and 51 of the Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that ICRA Limited has voluntarily reaffirmed the Credit Ratings, vide its letter dated February 24, 2026 for the following instruments of the Company:

Instruments	Amount (₹ crore)	Rating	Rating Action
Non-Convertible Debentures	5,000	(ICRA) AA+/Stable	Reaffirmed
Long-term/Short term fund based limits	1,250	(ICRA)AA+ (Stable)/ (ICRA)A1+	Reaffirmed

The above information will also be available on the website of the Company at www.mankindpharma.com.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer